Clinicopathological comparison and therapeutic approach to Castleman disease-a case-based review.
Castleman disease (CD)
benign lung lesion
lymphadenopathy
mediastinal tumor
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
entrez:
7
1
2020
pubmed:
7
1
2020
medline:
7
1
2020
Statut:
ppublish
Résumé
Castleman disease (CD) is a rare, B-cell lymphoproliferative disorder affecting lymph nodes and extranodal anatomical locations. Four types of clinical presentations can be distinguished after exclusion of mimics. The first division is into unicentric CD (UCD) and multicentric CD (MCD). MCD is classified further as HHV-8-negative (idiopathic), MCD associated with HHV-8 infection, and POEMS associated MCD. From the histological standpoint, UCD and MCD can be classified as hyaline-vascular (HV), plasma cell (PC), or mixed cellularity (MC) type, with a spectrum of histopathological manifestations. We present clinical and histopathological features and grading of 25 cases of CD classified according to CDCN histological criteria and according to this clinical algorithm, along with outcomes. Here we provide a fine-resolution description of the histological features of CD. We review and discuss the current diagnostic algorithm, grading system, and recently recommended treatment options. In the presented group of 25 patients with CD there were 14 women and 11 men in the age range 15-79 years. UCD was identified in 15 patients and it was most often located in mediastinum. MCD most frequently occurred as generalized lymphadenopathy. The most common type of CD was HV. All patients with UCD underwent complete surgical resection with a positive outcome. Patients with MCD had diagnostic partial surgical excision of the lesions, later followed by different types of treatment (corticosteroids, chemotherapy, radiotherapy, immunomodulatory agents) or 'watch and wait'. In four cases CD was associated with other malignancies (laryngeal cancer, small lymphocytic lymphoma, gallbladder cancer with hepatic metastases, primary squamous cell lung cancer). The accuracy of histopathological examination is essential and re-evaluation has to be performed in case of relapse or unexpected course of CD. Treatment tailored to fit the disease type and severity should follow the novel recommendations, including anti-IL-6 treatment in the case of MCD.
Identifiants
pubmed: 31903277
doi: 10.21037/jtd.2019.10.73
pii: jtd-11-11-4859
pmc: PMC6940266
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
4859-4874Informations de copyright
2019 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
SAGE Open Med Case Rep. 2017 Nov 30;5:2050313X17744481
pubmed: 29225882
J Hematol Oncol. 2014 Jan 17;7:10
pubmed: 24438824
Hum Pathol. 2013 Jun;44(6):1003-10
pubmed: 23260330
Hematol Oncol Clin North Am. 2018 Feb;32(1):37-52
pubmed: 29157618
Hematol Oncol Clin North Am. 2018 Feb;32(1):11-21
pubmed: 29157613
Blood. 2012 Mar 8;119(10):2228-33
pubmed: 22223822
Lung India. 2017 Mar-Apr;34(2):197-199
pubmed: 28360475
Virchows Arch. 2002 Oct;441(4):400-5
pubmed: 12404066
ScientificWorldJournal. 2009 Sep 14;9:940-5
pubmed: 19768350
Blood. 2018 Nov 15;132(20):2115-2124
pubmed: 30181172
Histopathology. 2001 Jun;38(6):510-8
pubmed: 11422494
Indian J Pathol Microbiol. 2016 Oct-Dec;59(4):446-456
pubmed: 27721273
Hematol Oncol Clin North Am. 2018 Feb;32(1):75-88
pubmed: 29157621
Cases J. 2008 Nov 19;1(1):330
pubmed: 19019227
Medicine (Baltimore). 2017 Sep;96(39):e8173
pubmed: 28953671
Ann Hematol. 2017 Dec;96(12):2117-2119
pubmed: 28861599
J Thorac Dis. 2018 Apr;10(4):2079-2088
pubmed: 29850111
Blood. 2010 Nov 25;116(22):4415-21
pubmed: 20688959
Clin Case Rep. 2018 Jan 22;6(3):473-475
pubmed: 29531720
Hematol Oncol Clin North Am. 2018 Feb;32(1):89-106
pubmed: 29157622
Radiat Med. 2006 Aug;24(7):529-33
pubmed: 17058149
Hematol Oncol Clin North Am. 2018 Feb;32(1):1-10
pubmed: 29157611
Oncol Lett. 2015 Aug;10(2):1041-1043
pubmed: 26622622
Ann Thorac Cardiovasc Surg. 2011;17(6):580-3
pubmed: 21881360
Blood. 2017 Mar 23;129(12):1646-1657
pubmed: 28087540
Am J Surg Pathol. 1987 Aug;11(8):618-24
pubmed: 3303982
J Cardiothorac Surg. 2014 Nov 28;9:170
pubmed: 25431102
J Blood Med. 2016 Aug 03;7:145-58
pubmed: 27536166
Ann Thorac Cardiovasc Surg. 2014;20 Suppl:689-91
pubmed: 24747548
Ann Thorac Cardiovasc Surg. 2016 Aug 23;22(4):258-60
pubmed: 26581496
Hematol Oncol Clin North Am. 2018 Feb;32(1):53-64
pubmed: 29157619
Blood. 2012 Jun 14;119(24):5650-8
pubmed: 22547581
Blood. 2018 Nov 29;132(22):2323-2330
pubmed: 30487129
J Med Case Rep. 2018 May 5;12(1):117
pubmed: 29728131
Am J Clin Pathol. 2011 Jun;135(6):901-14
pubmed: 21571963
Gen Thorac Cardiovasc Surg. 2017 Nov;65(11):664-666
pubmed: 28074445
Hematol Oncol Clin North Am. 2018 Feb;32(1):65-73
pubmed: 29157620
Adv Anat Pathol. 2009 Nov;16(6):392-404
pubmed: 19851130
Surg Today. 2004;34(9):772-3
pubmed: 15338352
Cureus. 2015 Nov 17;7(11):e380
pubmed: 26719823
Hematol Oncol Clin North Am. 2018 Feb;32(1):23-36
pubmed: 29157617
Jpn J Thorac Cardiovasc Surg. 2005 May;53(5):286-9
pubmed: 15952326
Adv Respir Med. 2018;86(1):36-43
pubmed: 29490420
Immunotherapy. 2016;8(1):17-26
pubmed: 26634298
Biores Open Access. 2018 Apr 01;7(1):47-51
pubmed: 29682404
Clin Adv Hematol Oncol. 2010 Jul;8(7):486-98
pubmed: 20864917
Br J Haematol. 2018 Jan;180(2):206-216
pubmed: 29143319